Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05429632 · ClinicalTrials.gov registry record · Phase 3
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
A Phase 3 study of Adult Acute Myeloid Leukemia, sponsored by Priothera SAS.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 366
- Enrollment target
- 20
- Study locations
NCT05429632 is a Phase 3 study of Adult Acute Myeloid Leukemia that is actively recruiting participants, run by Priothera SAS. The registered enrollment target is 366 participants. The trial reports 20 study locations across 16 states.
The verdict
NCT05429632, a Phase 3 study of Adult Acute Myeloid Leukemia, is actively recruiting participants, sponsored by Priothera SAS.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 366 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, randomized, double-blinded, placebo controlled trial.
Conditions Studied
Interventions
- DRUG mocravimod
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte - Duarte
- University of California Los Angeles (UCLA) - David Geffen School of Medicine - Los Angeles
Michigan
- Henry Ford Cancer Institute - Detroit
- Spectrum Health Medical Group (SHMG) - Blood & Marrow Transplant - Adult (BMT) - Grand Rapids
New York
- University of Rochester Medical Center (URMC) - Rochester
- Stony Brook University (SBU) - Cancer Center - Stony Brook
Ohio
- University of Cincinnati Medical Center (University Hospital) - Cincinnati
- The Ohio State University Comprehensive Cancer Center (OSUCCC) - Cleveland
Alabama
- University of Alabama Hospital (UAB Hospital) - Birmingham
Arizona
- Banner MD Anderson Cancer Center - Gilbert
Colorado
- UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center - Aurora
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 2022-06-16 |
| Est. Completion | 2029-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05429632
The ClinicalTrials.gov registry entry for NCT05429632 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 366 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Priothera SAS, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Adult Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which mocravimod is the first listed.
NCT05429632 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT05429632 about?
NCT05429632 is a clinical study titled "Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT". This is a multi-center, randomized, double-blinded, placebo controlled trial.
What is the current status of trial NCT05429632?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 366 participants. The study started on 2022-06-16. Estimated completion is 2029-11.
What conditions does trial NCT05429632 study?
This clinical trial studies the following conditions: Adult Acute Myeloid Leukemia.
What interventions are being tested in trial NCT05429632?
The interventions under investigation include: mocravimod (DRUG).
Who is sponsoring clinical trial NCT05429632?
This trial is sponsored by Priothera SAS, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05429632 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adult Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.